Özgür Aydın
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Özgür Aydın has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ismail Erturk
Gülhane Askerî Tıp Akademisi, Turkey (Türkiye)
5 shared publications Merve Dincer
Biochemistry Laboratory, Antalya Education and Research Hospital , Antalya, Türkiye
2 shared publicationsVolkan Karakus
Hematology Clinic, Antalya Education and Research Hospital , Antalya, Türkiye
2 shared publicationsEmel Caglar
Department of Medical Biochemistry , Gulhane Military Medical Academy , Ankara , Türkiye
1 shared publicationFatma Aykas
Antalya Research and Education Hospital, Hematology Clinic , Antalya , Turkey
1 shared publicationGuzin Aykal
Biochemistry Laboratory, Antalya Education and Research Hospital , Antalya, Türkiye
1 shared publication
Latest Publications
- Open Access
- 3 June 2026
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
Unnecessary serum electrophoresis testing in the follow-up of myeloma patients without detectable heavy-chain component
Objectives: The study aims to show that in the follow-up of light chain multiple myeloma (LCMM) patients using the electrophoresis tests as used in multiple myeloma (MM) patients with intact (heavy chain–associated) M protein, may cause unnecessary testing. Methods: The laboratory information system was searched retrospectively between 1 January 2022 and 31 December 2022. LCMM patients were characterized with positive urine immunofixation electrophoresis (UIFE), negative or positive serum immunofixation electrophoresis (SIFE), and both without any heavy chain component. Results: The randomly selected 10 patients were 5 males and 5 females, with a median follow-up time of 42 months (95 % CI 30–82 months). During the follow-up of the 10 patients, a total of 215 serum protein electrophoresis (SPE), 351 SIFE, and 306 UIFE tests were studied. Overall, 4 of the 215 SPE tests, 62 of 351 SIFE, and 142 of 306 UIFE tests were reported as positive. In 62 positive SIFE tests, 33 were evaluated to be due to Daratumumab drug interference. The other 29 positive SIFE tests were accompanied by concomitant positive UIFE tests. When scored according to the official scoring system (SUT), total SPE, SIFE, and UIFE tests performed in the follow-up of these 10 patients cost a total of 66,913 points. Negative SPE and negative or avoidable SIFE tests cost 38,764 of 66,913 points (58 %). Conclusions: The high rate of negative SPE and negative or avoidable SIFE tests indicated that the use of these tests should be carefully considered by the clinician in the follow-up of LCMM patients. Clinical guidelines should include clear directions for follow-up of subtypes of MM, particularly for LCMM.
- 3 June 2026
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
Open AccessUnnecessary serum electrophoresis testing in the follow-up of myeloma patients without detectable heavy-chain component
Objectives: The study aims to show that in the follow-up of light chain multiple myeloma (LCMM) patients using the electrophoresis tests as used in multiple myeloma (MM) patients with intact (heavy chain–associated) M protein, may cause unnecessary testing. Methods: The laboratory information system was searched retrospectively between 1 January 2022 and 31 December 2022. LCMM patients were characterized with positive urine immunofixation electrophoresis (UIFE), negative or positive serum immunofixation electrophoresis (SIFE), and both without any heavy chain component. Results: The randomly selected 10 patients were 5 males and 5 females, with a median follow-up time of 42 months (95 % CI 30–82 months). During the follow-up of the 10 patients, a total of 215 serum protein electrophoresis (SPE), 351 SIFE, and 306 UIFE tests were studied. Overall, 4 of the 215 SPE tests, 62 of 351 SIFE, and 142 of 306 UIFE tests were reported as positive. In 62 positive SIFE tests, 33 were evaluated to be due to Daratumumab drug interference. The other 29 positive SIFE tests were accompanied by concomitant positive UIFE tests. When scored according to the official scoring system (SUT), total SPE, SIFE, and UIFE tests performed in the follow-up of these 10 patients cost a total of 66,913 points. Negative SPE and negative or avoidable SIFE tests cost 38,764 of 66,913 points (58 %). Conclusions: The high rate of negative SPE and negative or avoidable SIFE tests indicated that the use of these tests should be carefully considered by the clinician in the follow-up of LCMM patients. Clinical guidelines should include clear directions for follow-up of subtypes of MM, particularly for LCMM.
- 3 April 2026
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 57 (3)
Suspicious bands in serum and urine protein immunofixation electrophoresis tests in patients with and without a history of monoclonal gammopathies: a retrospective database study
Introduction: Electrophoresis tests are reported as negative, positive, or—rarely—as suspicious for monoclonal band (SfMB). This study aimed to determine the fate of patients with SfMB findings in long-term follow-up. Methods: Patients with SfMB results obtained in 2019 were retrospectively identified. These patients were examined for the presence of any control electrophoresis test until their most recent hospital visit in 2025. Results: In 2019, electrophoresis tests were reported for a total of 1289 patients. In total, 115 patients with no prior electrophoresis test results were reported as positive (newly diagnosed patients) and 30 patients with no prior electrophoresis test results were reported as SfMB. Among the 30 SfMB cases, control electrophoresis tests had yielded a positive result in 2 patients and a negative result in 12 patients. In the remaining 16 patients, 7 were without control electrophoresis test results but had long clinical follow-up, whereas 9 were without a control electrophoresis test result and clinical follow-up. In 357 patients with a previously diagnosed monoclonal gammopathy, 18 were reported as SfMG. Discussion: None of the patients initially reported as having an SfMB developed monoclonal gammopathy during their follow-up period. We recommend that cases reported as “suspicious” be managed separately in patients with and without a prior monoclonal gammopathy diagnosis, where the term “weak positive” may be more appropriate in patients with a known monoclonal gammopathy.
- 3 April 2026
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 57 (3)
Suspicious bands in serum and urine protein immunofixation electrophoresis tests in patients with and without a history of monoclonal gammopathies: a retrospective database study
Introduction: Electrophoresis tests are reported as negative, positive, or—rarely—as suspicious for monoclonal band (SfMB). This study aimed to determine the fate of patients with SfMB findings in long-term follow-up. Methods: Patients with SfMB results obtained in 2019 were retrospectively identified. These patients were examined for the presence of any control electrophoresis test until their most recent hospital visit in 2025. Results: In 2019, electrophoresis tests were reported for a total of 1289 patients. In total, 115 patients with no prior electrophoresis test results were reported as positive (newly diagnosed patients) and 30 patients with no prior electrophoresis test results were reported as SfMB. Among the 30 SfMB cases, control electrophoresis tests had yielded a positive result in 2 patients and a negative result in 12 patients. In the remaining 16 patients, 7 were without control electrophoresis test results but had long clinical follow-up, whereas 9 were without a control electrophoresis test result and clinical follow-up. In 357 patients with a previously diagnosed monoclonal gammopathy, 18 were reported as SfMG. Discussion: None of the patients initially reported as having an SfMB developed monoclonal gammopathy during their follow-up period. We recommend that cases reported as “suspicious” be managed separately in patients with and without a prior monoclonal gammopathy diagnosis, where the term “weak positive” may be more appropriate in patients with a known monoclonal gammopathy.
- Open Access
- 18 February 2026
- Published by Galenos Yayinevi in Hamidiye Medical Journal
Newly Diagnosed Monoclonal Gammopathies in 2024 in a Single Center: A Retrospective Study from a Perspective of Initial Testing in Diagnosis
Newly Diagnosed Monoclonal Gammopathies in 2024 in a Single Center: A Retrospective Study from a Perspective of Initial Testing in Diagnosis - Hamidiye Medical Journal
- 18 February 2026
- Published by Galenos Yayinevi in Hamidiye Medical Journal
Open AccessNewly Diagnosed Monoclonal Gammopathies in 2024 in a Single Center: A Retrospective Study from a Perspective of Initial Testing in Diagnosis
Newly Diagnosed Monoclonal Gammopathies in 2024 in a Single Center: A Retrospective Study from a Perspective of Initial Testing in Diagnosis - Hamidiye Medical Journal
- Open Access
- 24 December 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 50 (1) , 32-36
Atypical cells parameter in sysmex UN automated urine analyzer: a single center study
Objectives: The literature about atypical cells in automated urine analyzers begins with the introduction of Sysmex UN. While modern urinalysis instruments report various kinds of epithelial cells, presence of atypical cells has not been considered. This study aims to observe the efficiency of the atypical cells parameter on Sysmex UN Automated Urine Analyzer with respect to customary manual urine cytology. Methods: The patients with any indication for a cystoscopy examination were enrolled for the study between March 2022 and October 2022. Voided urine samples were gathered before the cystoscopy and bladder washing sampling was performed afterwards. Bladder washing samples were divided into two; one part was sent for urine cytology and the other was sent for urinalysis. Bladder biopsy was performed if cystoscopy evaluation was suspicious for malignancy. Results: Thirty three patients (4 females and 29 males) underwent cystoscopy examination for suspicious bladder lesions and 15 of these patients were diagnosed as bladder cancer: nine were high-grade and six were low-grade bladder cancer due to their pathologic test results. Cytology examination results were negative for all patients. Using follow-up histologic diagnosis of urothelial carcinoma as a reference standard, the sensitivity of the atypical cells parameter on Sysmex UN was 27 %, specificity 78 %, positive predictive value 50 %, negative predictive value 56 %. Conclusions: The results of this study confirmed the ability of Sysmex UN on detecting atypical cells in urine. Yet, the performance of the instrument needs to be improved before the parameter is presented for routine application.
- 24 December 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 50 (1) , 32-36
Open AccessAtypical cells parameter in sysmex UN automated urine analyzer: a single center study
Objectives: The literature about atypical cells in automated urine analyzers begins with the introduction of Sysmex UN. While modern urinalysis instruments report various kinds of epithelial cells, presence of atypical cells has not been considered. This study aims to observe the efficiency of the atypical cells parameter on Sysmex UN Automated Urine Analyzer with respect to customary manual urine cytology. Methods: The patients with any indication for a cystoscopy examination were enrolled for the study between March 2022 and October 2022. Voided urine samples were gathered before the cystoscopy and bladder washing sampling was performed afterwards. Bladder washing samples were divided into two; one part was sent for urine cytology and the other was sent for urinalysis. Bladder biopsy was performed if cystoscopy evaluation was suspicious for malignancy. Results: Thirty three patients (4 females and 29 males) underwent cystoscopy examination for suspicious bladder lesions and 15 of these patients were diagnosed as bladder cancer: nine were high-grade and six were low-grade bladder cancer due to their pathologic test results. Cytology examination results were negative for all patients. Using follow-up histologic diagnosis of urothelial carcinoma as a reference standard, the sensitivity of the atypical cells parameter on Sysmex UN was 27 %, specificity 78 %, positive predictive value 50 %, negative predictive value 56 %. Conclusions: The results of this study confirmed the ability of Sysmex UN on detecting atypical cells in urine. Yet, the performance of the instrument needs to be improved before the parameter is presented for routine application.
- 16 April 2024
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 46 (5) , 963-965
Obinutuzumab interference with immunoelectrophoresis in a case of follicular lymphoma
- 16 April 2024
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 46 (5) , 963-965
Obinutuzumab interference with immunoelectrophoresis in a case of follicular lymphoma
- 22 August 2023
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 7 (2) , 82-85
Gama Alanında Ölçülebilir M Protein İçeren Multipl Miyelom Hastalarının Elektroforez ile Takibi: Laboratuvar Uzmanları İçin İyi Laboratuvar Uygulamaları
- 22 August 2023
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 7 (2) , 82-85
Gama Alanında Ölçülebilir M Protein İçeren Multipl Miyelom Hastalarının Elektroforez ile Takibi: Laboratuvar Uzmanları İçin İyi Laboratuvar Uygulamaları
- 16 March 2023
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 7 (1) , 40-42
Stepwise Testing in the Diagnosis of Monoclonal Gammopathies
- 16 March 2023
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 7 (1) , 40-42
Stepwise Testing in the Diagnosis of Monoclonal Gammopathies
- 13 March 2023
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 7 (1) , 40-42
Monoklonal Gamopatilerin Tanısında Basamaklı Test İstemi
- 13 March 2023
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 7 (1) , 40-42
Monoklonal Gamopatilerin Tanısında Basamaklı Test İstemi
- 29 December 2022
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 20 (3) , 136-137
Covid-19 Pandemisinde D-Dimer Testi Birimi Karmaşası
- 29 December 2022
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 20 (3) , 136-137
Covid-19 Pandemisinde D-Dimer Testi Birimi Karmaşası